Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GMED swine flu news! under .01!
GenoMed Offers Possible Alternative Treatment for Swine Flu
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—April 27, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that its concept of a general viral antidote may be especially useful for the current swine flu epidemic.
In Mexico, young, healthy people are dying from swine flu, as in the case of the 1918 epidemic. The press is finally reporting that this may be due to "cytokine storm." Healthy people mount an exaggerated immune response to a new virus, so that it's their own overly healthy immune system that kills them, rather than the virus itself. This is a new concept of viral diseases that GenoMed began promoting during the SARS epidemic six years ago.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Swine flu has two known treatments already, Tamiflu and Relenza. But for communities without access to these expensive medications, GenoMed offers the possibility that a cheaper and much more available class of medications, the ARBs (angiotensin II receptor blockers) or ACE inhibitors, which are present in every drug store on earth, may also work."
Dr. Moskowitz continued, "Anybody interested in our free clinical trial for swine flu is welcome to contact me at dwmoskowitz@genomed.com."
About GenoMed
GenoMed is a Next Generation Disease Management (DM) company that aims to deliver the best patient outcomes at the lowest possible cost. Being so active in clinically oriented research is what makes GenoMed a "Next Generation DM(tm)" company.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, especially whether our approach will actually work for swine flu, but also including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GMED swine flu news just out!
GenoMed Offers Possible Alternative Treatment for Swine Flu
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—April 27, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that its concept of a general viral antidote may be especially useful for the current swine flu epidemic.
In Mexico, young, healthy people are dying from swine flu, as in the case of the 1918 epidemic. The press is finally reporting that this may be due to "cytokine storm." Healthy people mount an exaggerated immune response to a new virus, so that it's their own overly healthy immune system that kills them, rather than the virus itself. This is a new concept of viral diseases that GenoMed began promoting during the SARS epidemic six years ago.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Swine flu has two known treatments already, Tamiflu and Relenza. But for communities without access to these expensive medications, GenoMed offers the possibility that a cheaper and much more available class of medications, the ARBs (angiotensin II receptor blockers) or ACE inhibitors, which are present in every drug store on earth, may also work."
Dr. Moskowitz continued, "Anybody interested in our free clinical trial for swine flu is welcome to contact me at dwmoskowitz@genomed.com."
About GenoMed
GenoMed is a Next Generation Disease Management (DM) company that aims to deliver the best patient outcomes at the lowest possible cost. Being so active in clinically oriented research is what makes GenoMed a "Next Generation DM(tm)" company.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, especially whether our approach will actually work for swine flu, but also including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GMED only swine flu play under .01
GMED only swine flu play under .01
Ibox updated showing bird flu applications of GMED. A possible swine flu play?
looks like we're going to be in for a big run on swine flu plays....all i see in the news is swine flu
great day here...looking forward to more
dshl volume alert
wow nice action
dshl guys primed for a run tomorrow
wow nice solid move today..must be a tight float...
getting a little action
looking really good...we may have found a good one here
wow another sell off today...anyone surprised by this?
very true...i agree that the selling has been overwhelming. the reverse split is the straw that broke the camel's back though. What this company needed was an investor with very deep pockets to ride out the bumps in the early stages. but instead it was dilute as much as possible and as fast as possible. I understand dilution happens with small companies. this was just too much and too fast. fundamentals need to develop a bit first, then money should be raised at higher incremental levels...not the opposite where money is raised at lower incremental levels, which is the sign of bad management.
the company burned the bridge...nobody is going to be buying on their prs anymore...I was stunned when they did that reverse..the outstanding shares weren't even that bad.
what the company fails to realize is that if they would have stayed away from the reverse split and then did their news campaign, then, the stock would be going up (in my opinion). But what they have done here is burn shareholders so bad, that they are no longer buying shares and are no longer supporting the company. They have essentially killed the golden goose. So with nobody left to support them, they sell, sell, sell as low as they can. Shameful. I wonder what jim brown and larry johnson think about all this? they are so far behind the scenes, one wonders if they know what is really going on. This company's performance has really made thest two sports heroes look bad. If I were them, I would get as far away from this company as possible. Here's a simple lesson in life HFBG: If you don't care for others, they won't care about you! In otherwords, your poor treament of your shareholders, means we no longer care about your company. I know this is penny land and its long odds here, but this whole reverse split thing was unnecessary, and poor judgement was used by management in my opinion, and it resulted in shareholders losing nearly 90% of its money for those who held post reverse.
already tried calling the TA...they will not give out the numbers...company policy of theirs..i guess that would require them to acutally do some work...look at a piece of paper and read off the number. their response was call the company.
the company's own ir guy doesn't know the outstanding...come on give me a break...i'm not going to give them a pass on that one. i've been looking at some of the filings though and it appears the ceo actually bought stock on the open market...about $7,000 worth.
i've also talked to her..she keeps telling me the ir guy is in a meeting lol
clearly that data is not accurate..we've traded 120 million today alone and were at triple zeros...there's definitely more than 300 million out on this.
what are the outstanding shares on this?
hi its been a while since i've looked at this stock..i thought it was going bankrupt...can someone give me a quick update? thx
A lot of sports stars just aren't business savvy and let managers like the current managemnt of hfbg drop elephant sized trds on poor shareholders like us. maybe if we can meet up with him, we can have the majority shareholders vote out the crap management and replace them with shareholder friendly people.
ya but what do you do when they reverse you out again? :(
nice news today....looking forward to seeing what the sample data will be
won't be long before we see triple zeros again on this one...appears they've fired up the printing presses again. If there are such big stars associated with this company, why don't they put their balls on the table and invest some money in this company instead of stealing shareholders' money non stop. reverse, print stock, drive to sub penny, repeat over and over. this company has zero credibility. If i were larry johnson and jim brown, I would be embarassed to be associated with it.
good lord, what has happened to the outstanding shares on this? i'm afraid i'm going to have to resign from this one. good luck everyone
nice development there...looks like it will be a busy summer for the company
nspt getting some mojo
looking solid
i doubt anybody has profits in this at all...maybe a few lucky people that bought at .0003. They reversed it at the low of lows so i'm sure almost everyone here has lost.
that pilot pr was total bs as well
see you later hfbv...this company is just beyond stupid...i've never seen such ineptitude. I was happy to get out at .0004 that was a gift given the continuing losses this company will cause for investors. unreal.
nice looks like things are back moving up
this stock is trading near its shell value...we just need to see the company communicate to the investing public (beyond newsletters to the people on this board) Hopefully we'll get some info soon on the reason for the large decrease in auth shares, which is great. I'm hoping we're in for a hot summer for hfbv.
stock market is going up every day lol...time for the company to come out of its shell and start talking to the public again :)
jsda announced improved numbers today...maybe that will mean the same for us...looks like with commodities down and fuel prices down, this may mean wider margins for hfbv. Sure would be nice to see a press release from this company sometime.
more news issued by the company via their web site:(none of these stories are hitting the newswires due to cost-cutting by the company, so nobody is really noticing the company right now.)
World Kidney Day / Groundhog Day? GenoMed Can Still Prevent Most Kidney Failure
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—March 12, 2009—GenoMed® (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company, announced again today, World Kidney Day, that it has found drug "recipes" to prevent most kidney failure.
The method was published in a peer-reviewed medical journal in September, 2002, but has received little publicity since.
GenoMed's approach reversed early kidney failure in white, black, and Hispanic patients with diabetes and high blood pressure. Diabetes and high blood pressure cause 90% of kidney failure in the US. Kidney failure affects people of color disproportionately more than whites.
The Centers for Medicaid and Medicare (CMS) currently pay $35 billion annually for kidney dialysis and transplantation. A typical dialysis patient costs $100,000 a year, and lives for less than 3 years on dialysis. When GenoMed's CEO, Dr. David Moskowitz, briefed CMS about his paper in 2004, the Medical Director and his staff at CMS had no interest. Neither did the National Institutes of Health, nor any non-profit kidney association, such as the National Kidney Foundation.
Said Dr. Moskowitz, "In medical school, we were exhorted to find cures. I wouldn't have believed it then if somebody had told me there was no point in finding a cure because news of the cure would be suppressed. Yet that's exactly what's happened for the past six and a half years."
Dr. Moskowitz continued, "Medicine, like any business, prefers the status quo. Small financial disruptions can be tolerated, like curing polio and TB in the 1950s. Other than the staff of the polio wards and the TB sanitaria, nobody in medicine was hurt financially. But eliminating 90% of a $35 billion a year industry is another thing altogether. Nobody in healthcare wants their budget or their revenues cut."
Dr. Moskowitz ended by saying, "If the President is to succeed at healthcare reform, he needs to realize this fundamental truth about the healthcare system: it will resist any attempt to reform it. But healthcare's days are numbered. GenoMed is leading the revolution towards preventive molecular medicine."
About GenoMed
In addition to avoiding dialysis in chronic kidney failure, GenoMed was also awarded a patent (6,998,404 B2) to treat acute kidney failure without dialysis. GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5-10 years. Patients with diabetes, hypertension, or emphysema are encouraged to contact Dr. Moskowitz about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
ya there needs to be some news released. putting out newsletters to current shareholders is nice, but that doesn't attract new ones.